European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Soraprazan - a new regenerative therapy for Stargardt's disease

Objetivo

Soraprazan – a new regenerative therapy for Stargardt’s disease
Abnormal accumulation of lipofuscin in the RPE cells is a hallmark in Stargardt's disease. As lipofuscin cannot be removed from the RPE cells in the eyes neither spontaneously nor with existing therapies, the accumulation of lipofuscin in the RPE cells of the eyes results in the degradation of the RPE cells and consequently in worsening of visual acuity and could lead to blindness. Soraprazan was able to show removal of lipofuscin in RPE cells. Aim of the phase II trial in this project is to evaluate savety and efficacy or orally taken Soraprazan treatment compared to placebo.

Convocatoria de propuestas

H2020-SC1-2016-2017

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SC1-2017-Single-Stage-RTD

Régimen de financiación

RIA - Research and Innovation action

Coordinador

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Aportación neta de la UEn
€ 467 500,00
Dirección
GESCHWISTER-SCHOLL-PLATZ
72074 Tuebingen
Alemania

Ver en el mapa

Región
Baden-Württemberg Tübingen Tübingen, Landkreis
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 467 500,00

Participantes (11)